Introduction
Chfr (checkpoint with FHA and RING domains) is a recently described mitotic checkpoint gene that transiently arrests cells in early prophase in the presence of microtubule poisons (Scolnick and Halazonetis, 2000) . The chfr gene has been linked to cancer. It is expressed ubiquitously in normal tissues, but in human cancer cell lines and in actual tumors, its promoter is frequently hypermethylated leading to loss of expression (Scolnick and Halazonetis, 2000; Mizuno et al., 2002; Shibata et al., 2002; Corn et al., 2003) . In addition, mutations in the chfr gene have been identified in human lung cancer (our own unpublished observations in collaboration with the team of Dr V Gorgoulis).
Despite its potential importance in cancer, the function of chfr is poorly understood. Experiments with synchronized cells suggest that chfr acts in early prophase before chromosomes condense, when the centrosomes move apart from each other along the periphery of the nucleus. If centrosome movement is inhibited by microtubule poisons, then chfr delays chromosome condensation and, therefore, progression from prophase to prometaphase (Scolnick and Halazonetis, 2000) .
The molecular mechanism by which the Chfr protein acts to delay chromosome condensation is obscure. At its N-terminus, Chfr has a forkhead-associated (FHA) domain. FHA domains from other proteins bind phosphopeptides (Durocher et al., 1999 (Durocher et al., , 2000 Liao et al., 1999; Wang et al., 2000) . The three-dimensional structure of the Chfr FHA domain bound to tungstate, an analog of phosphate, suggests that Chfr also recognizes phosphorylated proteins (Stavridi et al., 2002) . However, the identity of the Chfr ligands is currently unknown.
At its center, Chfr has a RING domain. This Znbinding domain is frequently present in proteins with ubiquitin ligase activity (Joazeiro et al., 1999; Levkowitz et al., 1999; Lorick et al., 1999) . Ubiquitin ligases function as part of an enzymatic cascade that leads to polyubiquitination of protein substrates (Ciechanover et al., 2000) . The first step in this cascade is the activation of ubiquitin by the ubiquitin-activating enzyme (E1). The second step involves transfer of ubiquitin from E1 to the ubiquitin-conjugating enzyme (E2) leading to the formation of a covalent thioester bond between ubiquitin and E2. In the final step, which requires a ubiquitin ligase (E3), ubiquitin is transferred to the protein target. Like many other proteins with RING domains (Joazeiro et al., 1999; Levkowitz et al., 1999; Lorick et al., 1999) , Chfr has ubiquitin ligase activity in vitro (Chaturvedi et al., 2002; Kang et al., 2002) . Accordingly, it has been suggested that Chfr establishes the early prophase checkpoint by targeting specific proteins for degradation. Indeed, in Xenopus extracts supplemented with high amounts of ubiquitin, recombinant Chfr polyubiquitinates Plk1, which is then degraded by the proteasome (Kang et al., 2002) . Plk1, a member of the polo family of protein kinases, promotes mitotic progression, so its degradation could explain how Chfr delays entry into prometaphase. Nevertheless, despite the attractiveness of this model, the evidence that the ubiquitin ligase activity of Chfr plays a role in protein degradation in vivo is weak. The only relevant observation is that in synchronized DLD1 colon carcinoma cells, the levels of ectopically expressed Chfr protein decrease dramatically in mitosis (Chaturvedi et al., 2002) . This decrease requires the RING domain of Chfr, implicating autoubiquitination and proteasomedependent degradation as the mechanism for regulation of Chfr protein levels in vivo.
Ubiquitin ligases that target their substrates for degradation in the proteasome typically catalyse the formation of polyubiquitin chains, in which the C-terminus of one ubiquitin molecule is attached via an isopeptide bond to Lys48 of another ubiquitin molecule. However, it has recently become apparent that not all ubiquitin ligases catalyse the formation of these so-called canonical polyubiquitin chains; some ubiquitin ligases catalyse the formation of noncanonical polyubiquitin chains, in which the isopeptide bonds involve lysines other than Lys48. A subset of these ubiquitin ligases catalyses the formation of Lys63-linked polyubiquitin chains and functions with a specific ubiquitin-conjugating enzyme consisting of a Ubc13-Mms2 heterodimer. The substrates of these ubiquitin ligases are usually not targeted for degradation, but are involved in signaling cellular stress (Hofmann and Pickart, 1999; Brusky et al., 2000; Deng et al., 2000; Ulrich and Jentsch, 2000; Xiao et al., 2000; Pickart, 2001; Wang et al., 2001; Torres-Ramos et al., 2002) . As Chfr plays a role in the response of cells to mitotic stress, we examined its specificity for ubiquitin-conjugating enzymes and the type of polyubiquitin chains that it catalyses. Contrary to the model that Chfr is involved in proteasome-dependent degradation (Chaturvedi et al., 2002; Kang et al., 2002) , we found that it shares functional properties with ubiquitin ligases involved in stress signaling.
Results
The Chfr protein contains a RING domain between residues 303 and 346 ( Figure 1a ). To characterize its ubiquitin ligase activity, a GST-Chfr fusion protein containing residues 281-543 of Chfr was incubated with ATP, E1, ubiquitin and various ubiquitin-conjugating enzymes. After 30 min, the GST-Chfr fusion protein was captured on glutathione beads and immunoblotted with antibodies that recognize ubiquitin to reveal polyubiquitinated products. As previously reported (Chaturvedi et al., 2002; Kang et al., 2002) , in the presence of UbcH5B Chfr became autoubiquitinated (Figure 1b) . We then explored whether Chfr had ubiquitin ligase activity, when incubated with other E2s. UbcH7 and UbcH8 did not function as E2s for Chfr. Ubc13 and Mms2 on their own were also inactive. However, the Ubc13-Mms2 heterodimer was a very efficient E2 for Chfr (Figure 1b) . A number of controls were performed to validate the ubiquitination assay. The reaction was dependent on E1, ubiquitin and GST-Chfr, as established by demonstrating that no polyubiquitinated products were formed when any one of these components was omitted from the reaction mixture or when GST-Chfr was replaced with GST ( Figure 1c) . Furthermore, the requirement for the presence of both Ubc13 and Mms2 is consistent with previous studies showing that Ubc13-Mms2 has E2 activity only as a heterodimer (Hofmann and Pickart, 1999; Brusky et al., 2000; Deng et al., 2000; Ulrich and Jentsch, 2000; Xiao et al., 2000; Torres-Ramos et al., 2002) .
Previous studies with Chfr and other ubiquitin ligases have mapped the ubiquitin ligase activity to the RING domain (Joazeiro et al., 1999; Levkowitz et al., 1999; Lorick et al., 1999 , Chaturvedi et al., 2002 Kang et al., 2002) . To determine whether the RING domain of Chfr is sufficient for Chfr to function with Ubc13-Mms2 as a ubiquitin ligase, various Chfr fragments were fused to GST and examined in ubiquitin ligase assays (Figure 2b) . Fragments containing the RING domain retained activity, whereas a C-terminal fragment encompassing residues 347-664 that does not include the RING domain lacked activity. Interestingly, fragment 281-375, which contains the entire RING domain, was less Purified GST or GST-Chfr fusion protein containing residues 281-543 of Chfr were incubated with purified E1, ubiquitin and ubiquitin-conjugating enzymes (UbcH5B, UbcH7, UbcH8, Ubc13, Mms2 or Ubc13-Mms2). The GST or GST-Chfr281-543 proteins were captured on glutathione beads and immunoblotted with an antiubiquitin antibody to monitor Chfr autoubiquitination. (c) Chfr ubiquitin ligase activity with Ubc13-Mms2 as the ubiquitin-conjugating enzyme requires E1 and ubiquitin. Ubiquitin ligase activity assays performed as described in (b) were repeated with one of the components omitted from the reaction mixture. Uq, ubiquitin; w/o, without active than fragments that extended more N-terminal (e.g., 1-375) or more C-terminal (e.g., 281-433). We speculate that sequences adjacent to the RING domain are either required for optimal ubiquitin ligase activity, for example, by recruiting Ubc13-Mms2, or that they serve as sites for polyubiquitination.
To identify more precisely the structural determinants for Chfr ubiquitin ligase activity, single amino-acid substitution mutants of Chfr were generated. Enzymatic activity was abrogated by substitutions targeting RING domain residues predicted to coordinate Zn (Figure 2a and c). An alanine substitution of a tryptophan conserved in several RING domain proteins, including Cbl (Joazeiro et al., 1999; Levkowitz et al., 1999; Lorick et al., 1999) , also eliminated ubiquitin ligase activity, whereas a more conservative substitution of this tryptophan with tyrosine reduced, but did not abolish activity ( Figure 2c ). In contrast, a substitution targeting cysteine 344, which is within the RING domain, but which does not coordinate Zn, and substitutions of cysteine 431 or 513, which are C-terminal to the RING domain, did not compromise ubiquitin ligase activity in vitro ( Figure 2c ). All Chfr mutants were examined using equal amounts of protein to ensure that the observed differences could be attributed solely to differences in enzymatic activity (Figure 2c , lower panel).
The ability of Chfr to function as a ubiquitin ligase with either Ubc13-Mms2 or UbcH5B raises the issue of specificity. The literature suggests that UbcH5B can function as an E2 for almost every ubiquitin ligase in vitro. If Ubc13-Mms2 was equally promiscuous in in vitro assays, then the observation that Chfr can utilize Ubc13-Mms2 as an E2 in vitro would not necessarily be relevant in vivo. To explore this issue, we examined the ability of Ubc13-Mms2 to function as a ubiquitinconjugating enzyme for Mdm2, a RING domain ubiquitin ligase, whose role in ubiquitin-dependent degradation of p53 is clearly established (Honda et al., 1997; Fang et al., 2000; Honda and Yasuda, 2000) . Mdm2 had no detectable ubiquitin ligase activity when incubated with Ubc13-Mms2, but was active when incubated with UbcH5B ( Figure 3a ). This result suggested that Ubc13-Mms2 is not a promiscuous E2 in vitro. However, an alternative explanation for this result might be that Ubc13-Mms2 was less active than UbcH5B in forming thioester conjugates with ubiquitin. If this was true and if, in addition, Mdm2 was an inefficient ubiquitin ligase under our reaction conditions, then Mdm2 might only function when incubated with the potent E2 (namely UbcH5B). To rule out this possibility, Ubc13-Mms2 and UbcH5B were incubated with E1, ubiquitin and ATP and the reaction products were immunoblotted for ubiquitin to detect E2-ubiquitin thioester conjugates. Since thioester conjugates are stable only in the absence of reducing agents, they can easily be identified by splitting the reaction products into two aliquots and treating each aliquot with or without reducing agents before polyacrylamide gel electrophoresis. By this analysis, Ubc13-Mms2 and UbcH5B did not differ in their ability to form E2-ubiquitin thioester conjugates (Figure 3b ). This result supports our conclusion that Ubc13-Mms2 is not a promiscuous E2 in vitro.
The specificity of Chfr for E2s was further evaluated by titrating the amount of Chfr added to the ubiquitin ligase reactions. At lower levels of Chfr, the levels of polyubiquitinated product decreased consistent with Chfr being rate-limiting (Figure 3c ). Under such conditions, the amount of polyubiquitinated product is proportional to the efficiency with which the E2 reacts with Chfr. In turn, this means that we can evaluate the preference of Chfr for various E2s by comparing the amount of reaction products. Quantitation of the intensities of the reaction bands reveals that under conditions in which Chfr is limiting (0.1 Â and 0.3 Â in Figure 3c ), Ubc13-Mms2 led to threefold higher amounts of reaction products than UbcH5B. Thus, in vitro Chfr has preference for Ubc13-Mms2 over UbcH5B.
Ubiquitin ligases that function with Ubc13-Mms2 typically form noncanonical polyubiquitin chains, in which the isopeptide bonds linking ubiquitin molecules to each other involve Lys63 of ubiquitin (Hofmann and Pickart, 1999; Deng et al., 2000; Pickart, 2001; Wang et al., 2001) . In contrast, ubiquitin ligases that target their substrates for proteasome-dependent degradation typically form polyubiquitin chains involving Lys48 of ubiquitin. To investigate the type of polyubiquitin chains formed by Chfr, we generated ubiquitin mutants in which either Lys48 or Lys63 was substituted with Arg. With UbcH5B as the E2, Chfr (and also Mdm2) formed polyubiquitin chains with wild-type ubiquitin, as Chfr functions with Ubc13-Mms2 J Bothos et al well as with the Arg48 and Arg63 ubiquitin mutants, suggesting that the isopeptide bonds linking the ubiquitin molecules did not involve exclusively Lys48 or Lys63. In contrast with Ubc13-Mms2 as the E2, Chfr formed polyubiquitin chains with wild-type ubiquitin and the Arg48 mutant, but not with the Arg63 mutant, suggesting that with Ubc13-Mms2 as the E2, the polyubiquitin chains formed by Chfr have isopeptide bonds that involve exclusively Lys63 of ubiquitin (Figure 4a ). The lack of ubiquitin ligase activity with the Arg63 mutant could not be attributed to an inability of Ubc13-Mms2 to form thioester conjugates with this ubiquitin mutant, as wild-type ubiquitin and both ubiquitin mutants were all efficiently conjugated to the Ubc13-Mms2 heterodimer (Figure 4b) .
It has been postulated that the ubiquitin ligase activity of Chfr is critical for its checkpoint function (Chaturvedi et al., 2002; Kang et al., 2002) . However, this has only been demonstrated using a Chfr RING domain deletion mutant (Chaturvedi et al., 2002) . To verify that the lack of checkpoint function is indeed attributable to loss of ubiquitin ligase activity and not to changes incurred on Chfr by deletion of its RING domain, we examined the Fusion proteins containing GST and residues 332-491 or 340-491 of human Mdm2 were assayed for ubiquitin ligase assay activity as described in Figure 1. (b) Comparison of the ubiquitin-conjugating activities of Ubc13-Mms2 and UbcH5B. Reactions were set up as described in Figure 1 , except that no Chfr was present. The reaction products were aliquoted and treated with (reduced) or without (nonreduced) reducing agents before gel electrophoresis. Immunoblotting with an antiubiquitin antibody indicates Uq and the Ubc (E2)-ubiquitin covalent complex (Ubc/Uq) in the nonreduced gel. (c) Ubiquitin ligase activity assays performed with Ubc13-Mms2 or UbcH5B as the ubiquitin-conjugating enzymes and varying amounts of GST-Chfr. The Â 1 amount of GST-Chfr corresponds to the amount used in all other experiments and the assay was performed as described in Figure 1 . The reaction products were quantitated by densitometry and the values (in arbitrary units) are shown below each lane Figure 4 Chfr catalyses the formation of Lys63-polyubiquitin chains when Ubc13-Mms2 functions as the E2. (a) Ubiquitin ligase activity of Chfr (residues 281-543) or Mdm2 (residues 332-491) incubated with wild-type Uq, Arg48 (R48) or Arg63 (R63)-ubiquitin mutants. The ubiquitin ligase assay was performed as described in Figure 1 with either UbcH5B or Ubc13-Mms2 as the E2. (b) Comparison of the ubiquitin-conjugation activity of Ubc13-Mms2 for wild-type Uq, Arg48 (R48) or Arg63 (R63)-ubiquitin mutants. The assay was performed as described in Figure 3b . Ubc/ Uq, Ubc13-ubiquitin covalent complex Chfr functions with Ubc13-Mms2 J Bothos et al checkpoint function of the Chfr RING domain single amino-acid substitution mutants described in Figure 2 . The various Chfr mutants and wild-type Chfr were transiently expressed in U2OS cells together with green fluorescent protein (GFP) as a marker of transfection efficiency; these cells were then treated with nocodazole and chromosome condensation was evaluated 16 h later. U2OS cells were selected for this experiment, because cell cycle delay in early mitosis in response to microtubule poisons is dependent on the activity of the transfected chfr genes (Scolnick and Halazonetis, 2000) . Ectopic expression of wild-type Chfr led to a reduction in the mitotic index (fraction of cells with condensed chromosomes), as compared to the vector control. However, the Chfr mutants that had lost ubiquitin ligase activity in vitro were inactive in this checkpoint assay (Figure 5a ). These results confirm the previous conclusion that Chfr ubiquitin ligase activity is required for checkpoint function. Most ubiquitin ligases target their substrates for degradation in the proteasome and it has been speculated that Chfr performs a similar function (Ciechanover et al., 2000; Chaturvedi et al., 2002; Kang et al., 2002 (Chaturvedi et al., 2002) . To determine whether this was a general phenomenon, we performed similar experiments with U2OS cells stably transfected with a plasmid expressing HA-tagged Chfr. These cells were synchronized at the G1/S phase boundary by a double thymidine-aphidicolin block and then released into the cell cycle to examine the levels of Chfr during entry into mitosis. Unlike the previous report, Chfr protein levels did not fluctuate in a cell cycle-dependent manner (Figure 5b ). Instead, we noted a modest change in Chfr electrophoretic migration from a doublet in the S phase and G2 to a single band corresponding to the more slowly migrating band of the doublet as cells passed through mitosis (14-16 h timepoint). The electrophoretic mobility shift was more pronounced when similarly synchronized cells were arrested in metaphase with nocodazole (Figure 5b) . Further, the electrophoretic mobility shift correlated with the presence of cells in mitosis and not with exposure to nocodazole. In the nocodazole-treated synchronized cells, the Chfr supershift was evident only when the cells accumulated in mitosis and not when nocodazole was added (Figure 5b) . Further, the Chfr supershift was evident in extracts of mitotis cells isolated by shake-off from an unsynchronized cell population not exposed to microtubule poisons (Figure 5c ). To identify the nature of the Chfr post-translational modification leading to the mobility shift, the cell extracts were treated with lambda phosphatase prior to electrophoresis. This treatment revealed that the change in electrophoretic migration was due to phosphorylation (Figure 5d ). We conclude that autoubiquitination-dependent degradation of Chfr is not a general phenomenon. In turn, this observation weakens the evidence in support of the model that in vivo Chfr targets itself and other proteins for degradation.
Discussion
The Chfr protein has many features characteristic of ubiquitin ligases. First, Chfr contains a RING domain, a type of domain associated with ubiquitin ligase activity that evidently functions by recruiting Figure 5 Requirement of Chfr ubiquitin ligase activity for checkpoint function and cell cycle-dependent phosphorylation of Chfr. (a) Mitotic index of U2OS cells transiently transfected with plasmids expressing wild-type or mutant Chfr proteins and GFP as a transfection marker after treatment with nocodazole. Cells expressing GFP were scored for chromosome condensation using a fluorescence microscope. Means and standard errors of three independent experiments are shown. (b) U2OS cells stably transfected with a plasmid expressing HA-tagged Chfr were synchronized with a thymidine-aphidicolin block. Cell cycle distribution (G1, S, G2 and M) was monitored by flow cytometry and Chfr protein levels and electrophoretic migration were monitored by immunoblotting at various timepoints after release from the cell cycle block, as indicated. The cells were treated with nocodazole (Nocod.) or solvent (DMSO) added 8 h after release from the cell cycle block. (c) The shift in electrophoretic migration of Chfr is observed in mitotic cells not exposed to microtubule poisons. Asynchronous populations of U2OS cells stably transfected with a plasmid expressing HA-tagged Chfr were used to prepare extracts (All) or were separated into mitotic (Mitot.) and nonmitotic (NonM.) populations by mitotic cell shake-off before preparing the extracts. The migration of Chfr was monitored by immunoblotting. (d) The shift in electrophoretic migration of Chfr in mitotic cells is due to phosphorylation. Stably transfected U2OS cells expressing HA-tagged Chfr were either unsynchronized (Asynch.) or enriched for mitotic cells by treatment with nocodazole for 16 h (Nocod.). Extracts from these cells were immunoblotted for Chfr after treatment with lambda phosphatase (PPase) or buffer, as described in Materials and methods ubiquitin-conjugating enzymes (Joazeiro et al., 1999; Levkowitz et al., 1999; Lorick et al., 1999; Ciechanover et al., 2000; Zheng et al., 2000) . Second, Chfr has an FHA domain, a type of domain involved in proteinprotein interactions (Durocher et al., 1999 (Durocher et al., , 2000 Liao et al., 1999; Wang et al., 2000; Stavridi et al., 2002) . Ubiquitin ligases typically contain protein-protein interaction domains to recognize their substrates. For example, the ubiquitin ligase Cbl has an SH2 domain to recognize its substrate epidermal growth factor receptor (Joazeiro et al., 1999; Levkowitz et al., 1999) .
Not surprisingly, the presence of RING and FHA domains in Chfr motivated efforts to determine whether it is also a ubiquitin ligase. Indeed, in vitro Chfr becomes autoubiquitinated when incubated with E1, ubiquitin, ATP and the ubiquitin-conjugating enzymes, UbcH4 or UbcH5 (Chaturvedi et al., 2002; Kang et al., 2002; this study) . In addition to its ability to ubiquitinate itself, Chfr can catalyse polyubiquitination and proteasomedependent degradation of Plk1 in Xenopus extracts (Kang et al., 2002) . These observations have led to the model that Chfr establishes an early prophase checkpoint by targeting specific proteins, such as Plk1, for proteasome-dependent degradation.
While the in vitro data are appealing, the evidence that Chfr targets proteins for degradation in vivo is weak. The only evidence in support of this model is that in synchronized cells the levels of ectopically expressed Chfr fluctuate in a cell cycle-dependent manner, whereas the levels of a deletion mutant that lack the RING domain are not cell cycle-dependent (Chaturvedi et al., 2002) . However, in a different cell line we were unable to reproduce this observation and instead observed cell cycle-dependent phosphorylation of Chfr that led to changes in its electrophoretic migration. The discrepancy may reflect different behavior of Chfr in different cell lines. Alternatively, the antibody used in the previous study to detect Chfr may not recognize the phosphorylated form, giving the impression that Chfr protein levels decreased. Irrespective of the explanation, the new results weaken the model that Chfr targets itself and other proteins for degradation in vivo.
An alternative model for Chfr function can be proposed on the basis of recent evidence suggesting that protein polyubiquitination may lead to fates other than degradation (Hofmann and Pickart, 1999; Brusky et al., 2000; Deng et al., 2000; Ulrich and Jentsch, 2000; Xiao et al., 2000; Pickart, 2001; Wang et al., 2001; Torres-Ramos et al., 2002) . Error-free postreplication DNA repair and NF-kB signaling require the activities of the RING domain ubiquitin ligases, Rad5 and TRAF6, respectively, which form noncanonical Lys63-polyubiquitin chains. The role of TRAF6 in the NF-kB signaling pathway may serve as a paradigm to understand how this family of ubiquitin ligases functions. In response to agents that activate NF-kB, TRAF6 becomes active as a ubiquitin ligase and polyubiquitinates itself; polyubiquitinated TRAF6 then activates the Tak1 protein kinase, which in turn through several intermediates, leads to the activation of NF-kB (Deng et al., 2000; Wang et al., 2001) . In this system, the Ubc13-Mms2 heterodimer is the ubiquitin-conjugating enzyme and Lys63-polyubiquitin chains are formed.
The findings reported here suggest that Chfr shares features with TRAF6. Both proteins can function with Ubc13-Mms2 as the ubiquitin-conjugating enzyme and both direct the formation of Lys63-polyubiquitin chains. In addition, like TRAF6 overexpressed Chfr can become autoubiquitinated in vivo (Chaturvedi et al., 2002; Kang et al., 2002) . These observations raise the possibility that the role of Chfr in the prophase checkpoint may not involve targeting proteins for degradation. Instead, Chfr may play a role in signaling the presence of mitotic stress caused by microtubule poisons, in a manner similar to that currently being elucidated for TRAF6 (Deng et al., 2000; Wang et al., 2001) . The availability of a second model for Chfr function provides a basis for novel experiments to elucidate its function at the molecular level.
Materials and methods

Recombinant protein expression and purification
Wheat his-tagged E1, human UbcH5B, UbcH7, UbcH8, Ubc13, Mms2 and ubiquitin were expressed in E. coli using pET-based plasmids (Novagen). Mutant forms of ubiquitin containing single amino-acid substitutions of Lys48 with Arg or Lys63 with Arg were generated by polymerase chain reaction-based mutagenesis. Glutathione-S transferase (GST), GST-Chfr and GST-Mdm2 fusion proteins were expressed using pGEX4T1-based plasmids (Pharmacia). His-tagged E1 was partially purified in four steps: chelating chromatography, gel filtration and two consecutive ion exchange chromatography steps using Resource Q and Mini Q columns (Pharmacia). UbcH5B, UbcH7, UbcH8, Ubc13, Mms2 and ubiquitin were purified by anion exchange chromatography followed by gel filtration. GST and GST-Chfr fusion proteins were purified by cation exchange chromatography, a batch purification step using glutathione-coated beads and gel filtration (Pharmacia).
Ubiquitin ligase assay
Ubiquitination reactions contained in a 100 ml volume 100 ng E1, 200 ng ubiquitin-conjugating enzyme, 1 mg ubiquitin and 1 mg GST, GST-Chfr or GST-Mdm2 fusion proteins in buffer consisting of 20 mm Tris (pH 7.4), 50 mm NaCl, 4 mm ATP, 0.2 mm DTT and 10 mm MgCl 2 . After a 30-min incubation at 301C, GST or the GST-Chfr fusion proteins were captured on glutathione-coated beads, unbound proteins were removed by washing the beads with buffer consisting of 50 mm Tris (pH 8.0), 120 mm Nacl, 0.5 mm EDTA and 0.5% NP-40 and the GST or GST-Chfr proteins bound to the beads were resolved by gel electrophoresis and immunoblotted with a polyclonal antibody that reacts with ubiquitin (Sigma). Some ubiquitination reactions were performed with threefold or 10-fold lower amounts of GST-Chfr to facilitate comparison of the specificity of Chfr for Ubc13-Mms2 versus UbcH5B.
Ubiquitin conjugation assay
Ubiquitin conjugation reactions contained in a 100 ml volume 10 ng E1, 200 ng ubiquitin-conjugating enzyme and 250 ng ubiquitin in buffer consisting of 20 mm Tris (pH 7.4), 50 mm NaCl, 4 mm ATP, 0.2 mm DTT and 10 mm MgCl 2 . After a 30-min incubation at 301C the reaction products were split into two aliquots. Both aliquots were subjected to gel electrophoresis and immunoblotting with a polyclonal antibody that reacts with ubiquitin (Sigma). However, for one aliquot the gel loading buffer did not contain a reducing agent to preserve the thioester bond linking the ubiquitin-conjugating enzyme to ubiquitin.
Mitotic index assay
U2OS osteosarcoma cells, which have a defective early prophase checkpoint (Scolnick and Halazonetis, 2000) , were cotransfected with 2.5 mg of a pSV2 plasmid with no insert or with inserts encoding various Chfr proteins (Scolnick and Halazonetis, 2000) and 0.5 mg of a plasmid expressing farnesylated GFP. After 48 h, the cells were treated with nocodazole (0.5 mg/ml) for 16 h, stained with Hoechst 33342, fixed in 2 % paraformaldehyde for 15 min at room temperature and mounted on glass slides using a cytospin centrifuge (Shandon). The mitotic index was determined by inspecting the cells with a fluorescence microscope (Leica). The experiment was performed in triplicate and for each datapoint 100 GFPexpressing cells were counted.
Cell cycle-dependent Chfr phosphorylation U2OS osteosarcoma cells were used to generate stably transfected clones expressing hemagglutinin (HA)-tagged Chfr protein using a pIRESN2 bicistronic plasmid (Clontech Laboratories). Colonies of stably transfected cells were selected with G418, expanded and screened for Chfr expression by immunoblotting. Clones expressing HA-tagged Chfr protein were synchronized in late G1/early S phase using a thymidine-aphidicolin block, as previously described (Scolnick and Halazonetis, 2000) . At various timepoints after release from the cell cycle block, cell cycle progression was monitored and extracts were prepared for immunoblotting. Some cells were treated with nocodazole added 8 h after release from the cell cycle block to enrich the population of mitotic cells. In a separate experiment, mitotic cells were isolated from untreated, unsynchronized cell populations by shake-off. Cell cycle progression was evaluated by flow cytometry monitoring phosphorylation of histone H3 on Ser10 using an H3 phosphospecific antibody (Upstate Biotechnology) and genomic DNA content by propidium iodide staining. To prepare extracts, the cells were lysed with buffer consisting of 50 mm Tris (pH 8.0), 120 mm NaCl, 0.5% NP40, 1 mm DTT, 0.4 mg/ml Pefabloc SC, 2 mg/ml pepstatin, 0.1 mm staurosporine, 15 mm NaF and 1 mm sodium vanadate. The lysates were cleared by centrifugation, resolved by gel electrophoresis and immunoblotted with an antibody that recognizes the HA tag (HA.11 mAb, Covance). The phosphatase assays were performed by immunoprecipitating HA-tagged Chfr from 100 mg cell lysate and incubating the immunoprecipitated proteins with 200 U lambda phosphatase (New England Biolabs) or control buffer at 301C for 30 min followed by gel electrophoresis and immunoblotting.
